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Protein-gold nanoparticle (AuNP) bioconjugates have many potential applications in
nanomedicine. A thorough understanding of the interaction between the protein and AuNP is
critical to engineering functional bioconjugates with desirable properties. In this work, we
investigate the role of free thiols presented by the protein on the stability of the protein-AuNP
conjugate. Human serum albumin (HSA) was modified with 2-iminothiolane (Traut’s reagent) to
introduce additional thiols on the protein surface, and three variants of HSA were synthesized to
present 1, 5, and 20 free thiols by controlling the molar excess of the chemical modifier. Protein
exchange studies on AuNPs were conducted using these HSA species and an IgG antibody which
exhibits 10 free sulfhydryls. Antibody-AuNP conjugates were synthesized, purified, and
dispersed in solutions containing each of the HSA species. No protein exchange was detected
with the HSA or modified HSA containing 5 thiols; however, 85% of the antibody was displaced
on the AuNP surface by the extensively thiolated HSA presenting 20 free thiols. Furthermore,
the impact of protein adsorption sequence was probed in which each of the HSA species were
pre-adsorbed onto the AuNP and dispersed in a solution of antibody. The antibody fully
displaced the HSA with a single thiol from the AuNP within 3 h, requires 24 h to completely
displace the modified HSA containing 5 thiols, and was unable to displace the modified HSA
containing 20 thiols. These results indicate that the number of Au-S interactions governs the

binding interaction between the protein and AuNP. This work provides further insight into the
protein-AuNP binding mechanism and identifies important design principles for engineered
proteins to optimize bioconjugates.
KEYWORDS: Protein adsorption; Bioconjugates; Chemical modification; Protein exchange
Nanomedicine
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CHAPTER I: INTRODUCTION

1.1. Gold Nanoparticles for Biomedical Applications
Gold, a very expensive inert substance, is one of the few elements that has diverse
applications: an essential commodity in the business world, an important element for artistic
designs, an antiquity of great importance, a rare commodity for trade exchange and an excellent
element for various manipulations in engineering, diagnostic, and biomedical applications.1-8
One of the various ways in which gold can be manipulated is through the chemical synthesis of
colloidal gold of varying sizes, surface charges, and shapes ranging between 1 – 100 nm in any
of their respective dimensions.9-11 This variety of sizes and shapes has led to tunable and unique
physicochemical properties. Moreover, research has shown that gold nanoparticles (AuNPs),
because of their large surface area to volume and high negatively charged surface, have strong
affinity for biomolecules (Figure 1).4 The unique properties of AuNPs, combined with the
controllable surface chemistry through adsorption of biomolecules, could be of great benefit in
the development of novel detection strategies that can identify disease biomarkers in their
minutest presence in biological samples.12-16
There has been an astronomical increase in demand for diagnostics and clinical tests due
to advancement in human and veterinary medicine. Advancement in human and veterinary
medicines require urgent need for enhanced sensitivity, specificity, improved detection limits
and throughput coupled with reduction in cost, complexity and assay time. These demands are
necessary to hasten detection, early diagnosis and treatments therefore minimizing the
unnecessary use of drugs, preventing the spread of diseases and decreasing the length of
hospitalization. A recent demand for such an advanced technique is the urgent need to curb the
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spread of covid 19 early diagnosis and containment of the infectious diseases.17-18 Covid 19 is a
pandemic that has resulted in death of more than 290,000 people and infected more than 4.3
million people across the globe within the first three months since the outbreak began. 17-18
A few NP-enabled technologies have been explored as alternative strategies to improve
medical diagnostics, imaging and drug delivery in order to meet these needs (Figure 2).19-20 Gold
nanoparticles have been exploited in many of these emerging technologies due to their unique
chemical, optical, electronic and catalytic properties.11 Our group and others have recently
developed AuNP enabled immunoassays that employ surface-enhanced Raman spectroscopy
(SERS) or dynamic light scattering (DLS) of the resulting aggregates for detection of infectious
diseases such as influenza virus.21-27 In these assays, AuNPs are precoated with specific antibody
(AuNP_Ab) and the resulting bioconjugate is introduced to biological sample (e.g blood) to
detect disease (antigen, At) in the matrix. The change in the unique optical properties of the
AuNP bioconjugates and the AuNP_Ab_At are then measured and quantified.

2

Figure 1. Interaction of gold nanoparticles with biomolecules.

Figure 2. Biomedical applications of gold nanoparticles using its unique optical properties.
3

Development of these AuNP-enabled immunoassays requires the immobilization of antibody to
AuNP. Thus, full understanding of the surface chemistry interaction between the antibody
(protein) and AuNP is key for optimization of such assays for early detection of diseases and
analytes in low concentration ranges. This understanding would help in tailoring the surface
chemistry of the AuNP for selective binding of the analyte of interest. The ideal immobilization
method would enable facile, reliable conjugation that could be universally applied for a wide
variety of antibodies and proteins.28

1.2. Immobilization Techniques
There are many known methods of immobilizing antibodies onto solid supports, such as
the surface of AuNPs. Immobilization chemistry is a critical factor since the protein loading and
orientation have a significant impact on the sensitivity of the resulting assay. Moreovever, the
protein-AuNP interaction must be robust to ensure the bioconjugate does not fail to perform its
function when applied to a biological system.29 Initial efforts to form protein-AuNP conjugates
were through direct adsorption of the protein to the AuNP, and this immobilization technique is
the most straightforward approach to forming stable bioconjugates. This approach is based on
electrostatic attractions between the negatively charged citrate capped AuNPs and the positively
charged surface of proteins as well as the hydrophobic interactions.30 It is worth noting that
hydrophobicity of PEGlated gold nanoparticles has been accounted to be responsible for
adsorption of more proteins from blood plasma.47,48 Additionally, the adsorption is often
accompanied by an entropic contribution to enhance the adsorption Though an easy technique of
forming bioconjugates, direct adsorption does not allow control over orientation of the
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immobilized protein which reduces the antibody binding activity.31 Moreover, it is often claimed
that bioconjugate formed through direct adsorption are susceptible to protein desorption since the
interaction is non-covalent. While studies have demonstrated that proteins adsorbed on AuNPs
can be displaced by proteins with greater binding affinities (Vrooman effect),32 an in-depth
understanding of the factors that control protein binding affinity may lead to successful
immobilization strategies and is the subject of this thesis.
In addition to direct adsorption, covalent immobilization of the proteins to form antibodyAuNP conjugates are commonly employed for commercial applications. In this approach,
AuNPs are first carboxylated and subsequently covalently attached to the antibody using
EDC/NHS chemistry. 23, 33-34 AuNPs can also be modified using a heterobifunctional crosslinker
such as 3,3’-dithiobis (sulfosuccinimidyl propionate) (DTSSP) or 3,3'-dithiobis (succinimidyl
propionate) (DSP) followed by conjugation to antibody through formation of an amide bond.35-45
The underlying principle exploits the primary amine of lysine residues that are ubiquitous to
protein to react with the succinimide on one end of the crosslinker, and the strong attachment
(covalent bonding) of thiol or disulfide functional group at the other end of the crosslinker (SH
or SS) to the AuNP for covalent attachment.19,20,46 Covalent immobilization often requires large
excess of protein because these amine reactive coupling chemistries are hindered by the rapid
hydrolysis rate compared to the aminolysis rate.31,47 Thus, this approach is an expensive and
time-consuming procedure. It is worth noting that recent reports have found that covalent
attachment of antibodies to AuNPs may not lead to improved bioconjugate performance or
stability as initially thought.48
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Scheme 1. Covalent formation of bioconjugates with associated challenges.
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Our group49 and others48 have systematically controlled the orientation of proteins on
AuNPs through pH modulations of the amine units on the lysine residues of the proteins and
PEGylated gold nanoparticle. By increasing the positive charge on the proteins through
protonation at lower pH, our lab confirmed that pH has a significant impact on the orientation of
proteins to citrate capped AuNPs while MerkoçI et al exploited a functionalised PEGylated gold
nanoparticle to obtain a fixed orientation of the proteins. We further sought to enhance a specific
orientation (optimized for maximum activity) of proteins to AuNP by gaining insight on the
mechanisms of these interations.

1.3. Role of Sulfhydryl Groups in Bioconjugate Robustness
Cysteine residues play an exclusive and essential role in protein structure, stability, and
function. Disulfide bonds between cysteine residues create an important skeleton that allows
proteins to achieve and maintain their three-dimensional structures. In order to understand
protein architecture and to detect anomalous disulfide bonding in recombinant proteins, there
have been many efforts to map the disulfide bonding in the proteins. However, less focus has
been directed towards free sulfhydryl despite increasing evidence that free sulfhydryl is directly
related to protein stability, aggregation, and affinity.50-54
Our group and others have recently developed AuNP enabled immunoassays that employ
surface enhanced Raman spectroscopy or dynamic light scattering of the resulting complex
(antigen-mediated of Ab-AuNP conjugates) for detection of diseases.21-27 The development of
the assays was based on a straightforward approach through direct adsorption of Ab onto AuNPs.
Because these immunoassays function by selectively binding targeted antigens in blood serum
for detection, displacement of the antibody from the AuNP by matrix proteins, or further protein
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adsorption to form multilayers, is a potential threat to antigen-mediated aggregation of the
conjugates. In our recent research work, we found more convincing evidence that contradict the
general believe that direct adsorption of antibody to AuNP is based on electrostatic interaction.
The outcome of these findings,30 and others,48 support the interaction between AuNP, and
antibody to be dative covalent in nature due to the irreversibility of the interaction which
contradicts electrostatic interaction.
To further substantiate this finding and come up with some key factors that would help us
with strategies to develop predictive models for the synthesis of robust conjugates for use in
immunoassays, we seek to understand the role of free thiol groups in the formation of a stable
and well oriented AuNP-antibody conjugate that could withstand complex biological matrixes.

1.4. Analytical Tools for Protein and Bioconjugate Characterization and Experimental
Studies
1.4.1. Dynamic Light Scattering
There are well-established techniques for the analysis of nanoparticles and protein
aggregates, prominent among them are analytical ultracentrifugation (AUC), asymmetrical flow
field-flow fractionation (AF4), dynamic light scattering (DLS), gel electrophoresis, size
exclusion chromatography (SEC), and scanning electron microscopy (SEM).55-57 Of these
techniques, DLS is most commonly employed because it is the most user-friendly, takes
relatively short period of time, and yields relatively more accurate and consistent results.56
Therefore, DLS has become the preferred technique to routinely determine the size of
nanoparticles among many other properties.

8

DLS is centered on the Brownian motion of dispersed particles. Particles dispersed in a
liquid move randomly in all directions. The principle of Brownian motion is that particles are
constantly bumping into solvent molecules. As a result of these collision, certain quantum of
energy is exchanged, which stimulates random movements within these particles. The smaller
particles move at higher speed than larger particles, because of the greater impact the energy
exchanged has on them. Additional parameters such as temperature and viscosity influence the
Brownian motion of the particles and form the basis of Stokes-Einstein equation in determining
the hydrodynamic diameter of the particles. 56-57
The simple setup of a DLS instrument is shown in Figure 3. A laser of a wavelength is
focused on the sample contained in a cuvette. Depending on the size of particles present in the
sample, the incident laser light gets scattered in all directions. It is worth noting that small
particles do not scatter much light, which leads to an insufficient signal. The scattered light is the
basis by which DLS discriminates between particles of different sizes. This can then be detected
at a defined angle of time with the resulting signal interpreted in terms of diffusion coefficient

and the particle size using the Stokes-Einstein equation :

Figure 3. Fundamental setup of a DLS measurement system. The sample is contained in a cuvette.
The scattered light from the incident laser can be detected at different angles.
9

Smaller particles do not only move at higher speeds but also show faster fluctuations in scattered
light intensity than larger particles as result of frequent collision with solvent molecules. The
larger particles account for higher amplitudes between the maximum and minimum scattering
intensities (Figure 4). This early intensity trace is further used to produce a correlation function.
The correlation function defines the duration a particle is located at a single spot within the
sample.
A

C

B

D

Figure 4. Differences in the intensity trace and correlation function of large (A &C) and small
particles (B&D). Smaller particles show faster fluctuations of the scattered light and a faster decay
of the correlation function.
DLS is used in the following studies to characterize formed bioconjugates and the data
obtained gives an insight into the experimental variables that impact the direct adsorption of
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proteins onto AuNPs. For instance, the data displayed in Figure 5 is the DLS measurement for a
bioconjugate synthesis carried out during the preliminary studies. Figure 5 shows the
correlogram (top) generated from the raw intensity fluctuations (lower left) and the histogram of
conjugate sizes (lower right) calculated using the Stokes-Einstein equation. It gives an insight to
particle size distribution, hydrodynamic diameter, polydispersity index and by comparing these
data with that of AuNP, it becomes possible to deduce if the protein adsorption and bioconjugate
synthesis was successful.

Figure 5. Typical result overview of a DLS measurement (HSA-AuNP bioconjugate). The initial
results (hydrodynamic diameter, polydispersity index) are displayed as well as information about
the correlation function (baseline, intercept, etc.).
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1.4.2. Nanoparticle Tracking Analysis
Notwithstanding being a powerful and accessible tool, DLS is not without drawbacks,
which are largely intrinsic to the principles of the technique. The determination of particle size is
determined from fluctuations in scattered light intensity as a result of the Brownian movement of
the particles.13 The fact that the intensity of the scattered light is related to the sixth power of the
particle diameter makes this technique very sensitive to the presence of large particles. This may
be desirable if the purpose is to detect small amounts of large particles, however it can be a key
drawback for accurately determining size of small particles in the presence of large particles.
Nanoparticle tracking analysis (NTA), commercialized in 2006, is an inventive system
for sizing particles from about 30 to 1000 nm, with the lower size limit being dependent on the
refractive index of the nanoparticles. This technique couples light-scattering microscopy with a
charge-coupled device (CCD) video camera, enabling the visualization and recording of
nanoparticles in solution under Brownian motion. The NTA software subsequently identifies and
tracks individual nanoparticles in motion under Brownian motion and interprets the movement to
a particle size according to the following formula derived from the Stokes-Einstein Equation.

12

Figure 6. Typical Overview of a DLS Measurement and Stoke’s equation.
Where, Dt = Translational diffusion coefficient [m²/s] – “speed of the particles”
kB = Boltzmann constant [m²kg/Ks²]
T = Temperature [K] ; 𝓃 = Viscosity [Pa. s]; DH = Hydrodynamic radius [nm]
Unlike DLS, NTA can provide sub-nanometer measurement of AuNP hydrodynamic
diameters and measures each individual particle without bias toward larger particle. Also, NTA
is not sensitive to proteins, since proteins do not scatter enough light to be visualized and
therefore does not require removal of excess, unbound antibodies for accurate analysis of the
conjugate, i.e., adsorbed antibody. In addition, NTA does not require labeling of the antibody;
techniques which require antibody labeling for analysis limit the accuracy of measured
adsorption parameters since labeling has been shown to alter antibody interactions with AuNP.5862

These attributes of NTA allow us to generate adsorption isotherms to quantitatively assess the

binding affinity of proteins in their native state to AuNPs under equilibrium conditions (Equation
1).
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𝐷! = 𝐷!,#$#%#&' +

(!,#$%&#'# [&$%#*+$](

[1]

-) ( .[&$%#*+$](

𝐷!,#$#%#&' is the initial hydrodynamic diameter of the bioconjugate
In this research work, we propose to determine the binding affinity of proteins and chemically
modified HSA in order to determine the role free thiol groups play in the adsorption and stability
of proteins onto AuNP.

1.4.3. UV-Vis Spectrophotometer
Ultraviolet and visible spectrophotometers have found a broad application for the past
three and a half decades. It is the most important analytical instrument in the modern-day
laboratory. Though other techniques have been developed for nanoparticle characterization, UVVisible spectrophotometry provides unparalleled simplicity, versatility, speed, accuracy and costeffectiveness.63
It is often referred to as electronic spectroscopy because it involves the excitation of the
electrons from ground state to the higher energy states. UV spectroscopy is a technique in which
light of the ultraviolet/visible region (200 – 800 nm) is absorbed by the molecule or analyte of
interest. Absorption of this high energy radiations or photons bring about promotion of the
electrons from the ground states to excited states.63 This absorption spectroscopy obeys the BeerLambert law in agreement with Equation 2:
A = log (I0/I) = Ecl

[2]

where, A = absorbance ; I0 = intensity of light incident upon sample cell; I = intensity of light
leaving sample cell ; C = molar concentration of solute ; L = length of sample cell (cm) ; E =
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molar absorptivity. Beer-Lambert law is best summarized as, the greater the number of
molecules capable of absorbing light of a given wavelength, the greater the extent of light
absorption. Based on this principle, proteins, gold nanoparticles–protein conjugates and gold
nanoparticles are capable of absorbing monochromatic light at different wavelengths and the
shift in the absorption wavelength and the narrowness of the absorption band can be employed as
a major characterization and quantitation tool.
AuNPs possess unique optical and physical properties which depend on size, shape,
surface structure and agglomeration stage. AuNPs exhibit a distinct optical feature commonly
called localized surface plasmon resonance (LSPR) resulting from the collective oscillation of
electrons in the conduction band of gold nanoparticles in resonance with a specific wavelength of
incident light. This LSPR is responsible for strong absorbance band in the visible region (500 nm
– 600 nm) and thus the peak absorbance wavelength increase observed for UV-VIS
spectroscopy. The peak absorbance is dependent on the size and shape of the nanoparticles due
to different refractive indices.
Due to the sensitivity of UV–VIS spectrophotometer to change in refractive index, UV–
VIS measurements can be used to evaluate the functionalization of gold nanoparticles.63 A red
shift of few nanometers in LSPR spectrum corresponds to binding of ligands to the gold
nanoparticle surface. In this research work, we employed the use of UV-VIS spectrophotometer
to study and confirm the conjugation technique employed in our lab.
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Figure 7. UV-VIS spectra of 60 nm gold nanoparticles, before (blue) and after (orange)
conjugation to an antibody. Note the 6 nm red shift of the LSPR peak while maintaining the
overall shape and intensity of the spectra indicating successful conjugation of the antibody to the
gold surface.
1.5. Overview of the Proposed Work
The development of an immunoassay that is capable of carrying out its functions in
complex biological samples such as blood or complex matrixes, would require an in-depth
understanding of how the most abundant blood protein, human serum albumin (HSA), and
perhaps other blood proteins influence the sensitivity and the stability of the assay towards the
detection of diseases. In this proposed study, we aim to pre-adsorb IgG to AuNPs and study the
sensitivity and stability of the resulting conjugates in blood proteins and vice versa. Further work
would be to chemically modify the most abundant blood protein, HSA in order to increase the
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number of free thiol moieties, quantify the number of free thiols present and study the ability of
IgG to displace it from the surface of the AuNP. The idea is that if increasing free thiol groups
correlated to increasing binding affinity of the protein to AuNP surface, then we would employ
increasing the number of free thiol on IgG through chemical modification in order to favor
stronger binding and possibly increased sensitivity of the assay for biodetection.
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CHAPTER II: QUANTITATION OF FREE SULFHYDRYL IN BLOOD PROTEINS

2.1. Introduction
The application of nanoparticles (NPs) offers an advancement of more effective, sensitive
and commercially viable biomedical technologies. Be it as drug delivery vehicles, active
therapeutics or high contrast imaging agents, NPs provide new pathways/strategies to be taken
for diagnosis, treatment or monitoring of diseases in the body.64,65 When not functionalized,
synthesized NPs are able to carry out their desired roles under controlled in vitro settings.
However, in more complex biological matrix like human blood, the affinity of NPs for
biomolecules (see Fig. 1 in Chapter 1) may hinder their activity, thereby posing many questions
on the specificity of NPs, the ability of the body to get rid of the NPs after its purposed activity,
the health impact of this and many others.
Current efforts to answer these questions is centered on the formation of peptide- or
protein-NP conjugates, with the nano-sized materials possessing the biological activity, and
biocompatibility essential for effective application in biomedical fields. While these properties
are very important, the effectiveness of the bioconjugate depends largely on its biological and
physical stability.51 This stability would determine the ability of bioconjugate to navigate its path
through an organization of complex biological obstacles, to resist replacement or displacement
by other biomolecules in the biological samples, and thus be able to reach the desired site of
action for its activity.64,65 Inability to successfully form a robust and stable bioconjugate implies
that the Vrooman effect would result in biomolecules present in the complex biological medium
competing with the proteins on the bioconjugate.73 The overall effect would be the inability of
the biconjugate to reach the target and perform its function.
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It is therefore of utmost important to develop a model for synthesizing robust protein-NP
conjugate that can effectively perform its function in any complex biological environment. Our
group recently investigated the nature of interaction between AuNPs and IgG antibody.30 In this
published work, our research efforts revealed that antibody irreversibly bound to AuNPs and
resisted displacement by blood proteins. As a result of this nature of interaction, we proposed
that free thiols play a role in this irreversible interaction. In this study we aim to further
substantiate this finding by carrying out a reverse exchange reaction and quantify free
sulfhydryls on plasma proteins.
Thiols are readily detected and quantified directly because of their relatively high
reactivity when compared to other species in biological systems. The most common quantitation
technique for free thiols employs the thiol - disulfide exchange reactions, which play essential
roles in cellular functions. Here, one of the sulfur atoms of the target disulfide bond is attacked
by a nucleophilic thiolate. The effectiveness and the rate of this attack depends on the
nucleophilicity of the attacking thiolate which is significantly influenced by pH of the reaction
medium, the pKa of the sulfhydryl, the steric and electrostatic effects.74 The more basic the
medium, the faster the reaction as the nucleophilicity is enhanced, due to equilibrium favoring
the dissociation of the thiols to thiolates.75 Biological thiols show a broad pH range which
accounts for a significant shift in magnitude of the deprotonation equilibrium. This equilibrium
determines the concentration of the thiolate using Henderson – Hasselbalch equation for reaction
kinetic relationship.76
There are many colorimetric methods (reagents) for quantifying free sulfhydryl, most of
which employs the thiol – disulfide reaction mechanism. In addition to this, fluorometric
detection of thiols and formation of detectable thiol adducts using gel-shift assays are some of
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the common methods suitable for detection and quantitation of free thiols though sensitivity of
each assays differs.77 Many functionalized labeling reagents that centered on the selective thiol
reactivity with disulfide, maleimide or iodoacetate moieties are available commercially. Most of
these reagents possess easy readout of the free thiols through coupling with reporters which act
as radiolabel, fluorophore or chromophore.76 Ellman’s reagent is a typical example of a
chromogenic reagent for measuring the total free sulfhydryl in biological samples. Ellman’s
reagent, 5, 5’–dithiobis–(2-nitrobenzoic) acid, also called DTNB, possesses a highly oxidizing
disulfide bond which can be stoichiometrically reduced by free thiol in a thiol-disulfide exchange
reaction to yield a mixed disulfide and a molecule of 5-thio-2-nitrobenzoic (TNB). As an
excellent leaving group with pKa of 4.5, TNB is easily released for every thiol oxidized when
treated with DTNB (Figure 8).77,79,80

Figure 8. Schematic spectrophotometer analysis of Ellman’s reagent chemical reaction with
protein or biomolecules for thiol quantitation.
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Figure 9. Schematic spectrophotometer analysis of Ellman’s reagent chemical reaction with
cysteine standards for calibration plot.

TNB is a yellow solution, the intensity of which can be correlated to the number of free
thiols in the biological molecule using UV-visible spectrophotometer or microplate reader
(Figure 9). Throughout this research work, we employ the use of microplate reader because it
requires a smaller volume of the sample.
2.2. Experimental
2.2.1. Chemicals
All studies were conducted using citrate-capped, spherical gold nanoparticles (AuNPs)
purchased from Ted Pella Inc. (Redding, CA) with a nominal diameter of 60 nm. The
hydrodynamic diameter of the AuNPs measured 60.3 ± 0.6 nm via nanoparticle tracking analysis
with a zeta potential of −40 ± 1 mV. Mouse anti-HRP monoclonal antibody (4.4 mg/mL) was
obtained from MyBiosource. The blood plasma proteins, human serum albumin (HSA),
fibrinogen, and transferrin were all obtained from Sigma-Aldrich (St. Louis, MO). Horseradish
peroxidase (HRP) and 2,2′-azino-bis(3- ethylbenzothiazoline-6-sulfonic acid (1-Step ABTS)
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were purchased from Thermo Scientific (Rockford, IL). Potassium phosphate monohydrate was
acquired from Fisher Scientific (Fair Lawn, NJ), and anhydrous potassium phosphate dibasic was
purchased from Mallinckrodt Chemicals, Inc. (Paris, KY). Nanopure deionized water (18 MΩ)
produced from a Barnstead water purification system (Thermo Scientific, Rockford, IL) and used
to prepare all aqueous solutions.

2.2.2. Quantifying Free Thiols in Proteins with Ellman’s Reagent
The concentration range of cysteine calibration standard solutions was optimized to
ensure the linear range of the calibration curve would allow for quantitation of analyte of interest
in the biological sample. In this assay, 12.1 mg of cysteine was dissolved in the reaction buffer
(0.1 M sodium phosphate, pH 8.0, containing 1 mM EDTA) to prepare a working stock of 1000
mM cysteine standard. The working stock was serially diluted to obtain various calibration
standards.
Pure protein samples of known concentration (10 𝜇L), which included fibrinogen, human serum
albumin (HSA), transferrin and anti-HRP monoclonal antibody (AHRP) were also prepared in 2
mM phosphate buffer pH 7.4 in order to estimate the number of free sulfhydryl present in the
respective protein samples.
Following manufacturer’s protocol, 4 mg of DTNB, the free thiol quantifying reagent,
was dissolved in 1 mL of reaction buffer (0.1 M sodium phosphate, pH 8.0, containing 1 mM
EDTA). 3.5 𝜇L of the resulting solution was applied to each well in a 96-well plate already
containing 46.5 𝜇L of the reaction buffer. 10 𝜇L of each cysteine standards and protein samples
were introduced to corresponding wells in triplicates. The resulting mixture was incubated for 15
minutes, and the absorbance of each well was measured at 415 nm. A calibration curve was
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plotted and used to quantify the absolute number of free thiol groups in each of the blood
proteins and antibody.

2.2.3. Reduction of Accessible Disulfide Bonds in Biomolecules
It is well established that disulfides cleave in the presence of a gold surface to form a AuS bond, similar to that formed from a free thiol. Thus, the presence of surface accessibility
disulfides on proteins could lead to a thiolate bond between the protein and AuNP surface, yet go
undetected by Ellman’s reagent. Therefore, in an effort to also measure potential immobilization
through protein disulfides, surface accessible disulfides on the proteins were reduced to thiols
prior to quantification with Ellman’s reagent. There are three main factors desired for effective
reduction of disulfides in biomolecules for further analysis. The desired factors include 1) the
reductant selected should not influence or complicate downstream reactions and treatments of the
reduced biomolecules; 2) It should be specific and not show significant side reactions; 3) Lastly,
the disulfide reduction should be rapid and quantifiable. In order to meet these three
requirements, TCEP (Tris[2-carboxyethyl] phosphine hydrochloride) immobilized onto 4%
crosslinked beaded agarose was used. Known as a highly efficient agent for reducing disulfide
bonds in proteins and many biomolecules over a wide pH, TCEP is odorless and stable in
aqueous solutions. It does not interfere with commonly used sulfhydryl – reactive reagents.
Being immobilized on a resin facilitates the removal of the reduced samples from the reducing
agents or other side products.
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Scheme 2. TCEP mechanism of action.

Following the manufacturer’s protocol with modification to the incubation time set at 15
minutes, the disulfide reductions of HSA and AHRP were performed. 50 𝜇L of the TCEP resin
in a low binding tube was centrifuged at 1000 g for 1.5 minutes, the supernatant was removed
and discarded. The gel was then washed three times with sample buffer (2 mM sodium
phosphate, pH 7.4), with each wash involving the introduction of 25 𝜇𝐿 of the sample buffer to
the gel, followed by a brief vortex to resuspend the gel. This was followed by centrifugation at
1000 g for another 1.5 minutes, the supernatant was removed and discarded. 25 𝜇𝐿 of the protein
sample is then introduced after the washing, vortexed and allowed to incubate for 15 minutes at
room temperature. The reduced sample was removed as supernatant after centrifugation. The
number of free thiols in the reduced proteins were quantified with Ellman’s reagent as described
in Section 2.2.2.
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2.2.4. Chemical Modification of Protein
2.2.4.1. Modification of HSA with Traut’s Reagent
Traut’s reagent (2-iminothiolane) is a small molecule capable of reacting with primary
amines (e.g. lysine side chain) leading to the formation of free thiol/free sulfhydryl group and an
amide bond. Essentially, this thiolation compound can be employed to increase the number of
free sulfhydryl group in biomolecules.
Two-fold molar excess of Traut’s reagent was added to known concentration of HSA and
the resulting mixtures were incubated for approximately 60 minutes. Following manufacturer’s
protocol with little modification, a Zeba Desalting column was employed to separate
unreacted/excess Traut’s reagent from the chemically modified HSA (referred to as THSA) and
the resulting protein concentration was determined using a Nanodrop 2000. The number of free
thiols in the reduced proteins were quantified with Ellman’s reagent as described in Section
2.2.2.

2.2.4.2. Modification of HSA with DSP
Lomant's Reagent, dithiobis (succinimidyl propionate) is a homobifunctional crosslinker
that is reactive towards amine (amino) functional groups leading to the formation of free
thiol/free sulfhydryl group with an amide bond. Essentially, this thiolation compound can be
employed to increase the number of free sulfhydryl group in biomolecules. A two-fold molar
excess of DSP was added to known concentration of HSA and the resulting mixtures were
incubated for about 60 minutes. Following manufacturer’s protocol with little modification, a
Zeba Desalting column was employed to separate unreacted/excess DSP reagent from the

25

chemically modified HSA (referred to as DHSA) and the resulting protein concentration was
determined using a Nanodrop 2000. The number of free thiols in the reduced proteins were
quantified with Ellman’s reagent as described in Section 2.2.2.

2.2.5. Synthesis of Protein-AuNP Conjugates
The bioconjugates were prepared by loading 100 μL of 60 nm AuNPs suspension in a
low binding tube followed by centrifugation at 5000g for 5 minutes. The supernatant was
discarded, and the pelleted AuNPs re-suspended in 2 mM phosphate buffer at pH 7.4. Known
concentration (enough to ensure formation of monolayer) of the appropriate proteins (60 µM
HSA and THSA, DHSA or anti-HRP antibody) were then added, vortexed to
ensure a homogeneous mixture was obtained, and incubated for 60 minutes at room
temperature on a rotor.

2.2.6. Protein Displacement Studies
Displacement studies of the AHRP-AuNP bioconjugates synthesized above by HSA,
THSA and DHSA was carried out following the procedure depicted in Figure 11. The proteinAuNP bioconjugates were purified to remove unreacted and poorly bound proteins by
centrifuging at 5000 g for 5 min, the supernatant was discarded and the bioconjugate pellets
resuspended in 2 mM phosphate buffer (pH 7.4). The procedure is repeated 4 times (an
established purification steps) to ensure all excess components are removed. Known
concentration of a competing protein is then introduced into the conjugate, the resulting
suspension vortexed and incubated for 3 and 24 h to allow for potential protein exchange. The
conjugate was then centrifuged/resuspended four times to remove any unbound proteins.
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To quantify the antibody immobilized on the AuNP, HRP (3 mg) was added to the
conjugates and allowed to react for 3 h. The conjugates and any bound HRP were then purified
via four centrifugation/resuspension cycles. The quantity of bound HRP was quantified via a
previously developed enzymatic assay and functions as an indirect measure of immobilized
antibody on the AuNP.30

2.2.7. Quantification of AuNPs with ICP-OES
To ensure accurate measure of the extent of the displacement, the number of AuNPs
present in each of the sample is quantified and used to normalize the kinetic rates. To achieve
this, 50 µL of the sample is loaded into a low binding tube and 5 µL of 100 mM potassium
cyanide was added to dissolve the AuNPs and thus proteins for direct quantitation of Au present.
After the dissolution, a clear solution is obtained. 50 µL of the resultant solution is added to
4950 µL of 2 % nitric acid in appropriate glassware. The prepared samples are then analyzed
using ICP-OES with intensity obtained corresponding to the concentration of AuNPs present.

2.3. Results and Discussion
2.3.1. The Role of Electrostatic Forces in the Adsorption of Protein to AuNPs
Our group recently discovered the strong affinity of antibody for AuNPs and the
resistance of the resulting bioconjugates to displacement by blood proteins such as fibrinogen,
transferrin and HSA.30 In this study, we sought to understand the chemistry behind these
interactions, with the aim of exploring such chemistry in various biomedical applications. AuNPs
employed in this research had a negative surface charge of approximately -46 mV, as determined
by zeta potential measurements. Therefore, electrostatic force would have a role to play in the
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adsorption of proteins to such a surface. Though the binding affinity was not investigated in this
research work, our group and others recently established the influence of pH on the orientation of
antibodies on AuNP,49 thereby confirming the possibility of electrostatic influence on the
interaction of proteins with AuNP. Despite this potential interaction, gold affinity for sulfur is
well-established.30 To ascertain, and thus tailor, this research work, we chemically modified
HSA with equal molar excess of DSP and Traut’s reagents. One mole of DSP reacts with two
amine units of lysine residues to increase the freely accessible thiols by two, this would result in
corresponding decrease in the surface charge of the proteins. On the other hand, one mole of
Traut’s reagent reacts with one amine unit of the lysine residues to increase the freely accessible
thiols by one while maintaining the same or relatively close surface charge of the protein.
The idea is to establish the correlation and the important roles surface charge and number
of free thiols play on proteins’ relative affinity for AuNP. Results of the displacement studies
revealed that DHSA resisted displacement by antibody on the AuNP surface approximately four
times better than THSA as displayed in Figure 12.
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Table 1. A brief summary of all the abbreviations and their respective experiental conditions and
results.

Abbreviations Description

Number Number of
of lysine cysteine
residue residue

HSA

59

35

No of Thiols
after
chemical
modification
1.2

78

34

0

N/A

N/A

3

N/A

N/A

6

N/A

N/A

6

N/A

N/A
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AHRP/IgG
THSA
DHSA
20T_HSA
30T_HSA

Human Serum
Albumin
Monoclonal Anti
Horesdish Peroxidase
(antibody)
2-fold molar excess
Traut's reagent
2-fold molar excess
DSP
20-fold molar excess
Traut's reagent
30-fold molar excess
Traut's reagent

This outcome revealed that while surface charge may facilitate the binding of protein to AuNPs,
free thiols are significantly more responsible for forming an irreversible binding of the
bioconjugates, because the less positively charged DHSA (with more thiols) resisted being
displaced by antibody much better than the more positively charged THSA protein. Thus, we
tailor our studies to determine the role and extent of impact free thiols have in protein adsorption
to AuNPs.
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Figure 10. Schematic representation of the hypothesis.

Figure 11. Schematic representation of the displacement studies.
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Figure 12. Displacement studies of DSP (HSA-Dsp) and Traut’s (HSA-Trt) modified HSA
revealing the impact of increasing Free sulfhydryl groups and surface charges.

We hypothesize based on this finding, that this strong affinity and resistance to antibody
displacement was due to increase in the number of free thiols accessible for binding to the AuNP
surface rather than electrostatic attraction resulting from different surface charges on proteins
and AuNPs. While not totally implying that electrostatic interaction is not important in this
binding, our perspective is that the first force that attracts protein to the AuNP surface might
have been electrostatic in nature. However, the actual interaction that leads to formation of a
robust bioconjugate is the Au-S bond.
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2.3.2. Quantifying Free Thiols in Blood Proteins and Antibody
Considering the inference drawn from the studies above, we proceeded to correlate the
role of thiols in formation of robust and stable bioconjugates by blood proteins and antibodies. In
the first step, we quantify the number of free sulfhydryl in blood proteins and antibody using
Ellman’s reagent. A representative calibration curve provided in Figure 13 demonstrates the
linear relationship between the concentration of free thiol in the sample and the measured TNB
product. However, we could not detect any free thiol in the antibody, contrary to what would
have been expected based on the strong affinity of the antibody for AuNPs.39 We explored the
use of a more sensitive fluorescence assay (Thiol Kit Assay) to further probe the existence of the
free sulfhydryl in the antibody (Figure 14).
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Figure 13. The calibration plot of cysteine standards using Ellman’s reagent.
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Figure 14. The calibration plot of cysteine standards using Measure-ITTM Thiol Assay Kit.

While the results agree with Ellman’s reagent quantitation and confirmed the
effectiveness of this reagent in quantifying free thiols, free thiol was still not detected in the
antibody. It has long been established that accessible disulfide bonds are readily reduced in the
presence of Au to facilitate the formation of Au–S bond.81 We explored this probability by
partially reducing the freely accessible disulfide bonds in antibody and HSA using resinsupported TCEP. The reduced proteins were further analyzed for free thiols using Ellman’s
reagent immediately after the TCEP reduction. Results revealed that antibody possesses
approximately five disulfide bonds that are solvent accessible which were reduced by the TCEP
while HSA has no solvent accessible disulfide bonds as the number of thiols after the reduction
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was essentially the same as before the reduction. The results of these analyses are shown in
Table 2.

Table 2. Accessible free thiols in proteins and TCEP reduced proteins as quantified with
Ellman’s reagent.
Protein

No of Free Sulfhydryl per protein

HSA

1.3 ± 0.6

Fibrinogen

3.0 ± 1.2

Transferrin

0.8 ± 0.03

HSA (Reduced with TCEP)

1.0 ± 0.003

AHRP (Reduced with TCEP)

10.0 ± 0.06

Molecular dynamic studies using UCF chimera 82 and bioinformatics database83 revealed two
thiol in HSA (PDB: 1UOR) with relative solvent accessibility of 4 which could correlate to one
thiol experimently when considering that the thiol residue are barely accessible to solvent (Figs.
15 & 16 respectively).82,83 The outcome of these theoretical studies and simulation agrees with
experimental data using Ellman’s reagent and Thiol Kit Assay.
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Figure 15. The helical structure of HSA (PDB: 1UOR) structure from UCF Chimera software.
Disulfide in yellow and thiol in green.

Figure 16. The solvent accessibility information of freely accessible thiol in HSA.75
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2.3.3. Displacement Studies of Blood Proteins
Protein exchange studies were carried out to determine if the protein-AuNP interaction
correlates with the number of free thiols. We hypothesized that a pre-adsorbed protein could
resist displacement by a competing protein in solution, only if the adsorbed protein presents a
greater number of free thiols for binding to the AuNP than the competing protein. Conversely,
the pre-adsorbed protein on the AuNP could be displaced by any protein in solution displaying
more free thiols. To test this hypothesis, we used a previously developed enzyme assay.30,49
Given that the antibody binds HRP, an enzyme that catalyzes the oxidation of ABTS to produce
a colored product, the number of immobilized antibody can be determined by the enzymatic
reaction rate achieved by the conjugates that are saturated with bound antigen. Thus, a greater
reaction rate would suggest more immobilized antibody. As negative control conjugates, the
blood proteins are pre-adsorbed onto AuNP, incubated with HRP, and the enzymatic reaction
rate is measured. The blood proteins do not bind HRP, thus any enzymatic reaction is due to nonspecific binding of HRP and is expected to be low. As a positive control, antibody is preadsorbed onto AuNP, incubated with HRP, and the enzymatic reaction rate is measured. This
conjugate should give a maximum reaction rate since the conjugate is loaded with antibody and
did now allow for displacement of the antibody.
In our first series of displacement studies, antibody was pre-adsorbed onto the AuNP and
incubated with the competing blood proteins, fibrinogen, HSA, and transferrin, respectively
(Figure 17). As is evident, the enzymatic activity of these conjugates remained high, nearly
equivalent to the positive control sample, indicating no displacement of the antibody by the
serum proteins. Moreover, the negative control samples provided very little enzymatic activity to
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confirm specificity of our assay. These results are consistent with previous work conducted and
published by our laboratory.30
We subsequently carried out displacement studies by coating AuNPs with the respective
blood proteins and studied their resistance to displacement by antibody. The displacement
studies revealed varying levels of displacement of the blood proteins by the antibody (Figure 8).
Fibrinogen, which has the highest number of free thiols (Table 2), exhibited the greatest
resistance to displacement by antibody, while HSA, which displayed the fewest free thiols of the
proteins (Table 2), showed the least resistance. Based on these results, we conclude that the
strength of the protein-AuNP interaction correlates with the number readily accessible thiols in
proteins.
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Figure 17. Displacement studies of blood proteins by IgG. (A) Fibrinogen (B) HSA (C)
Transferrin.

In agreement with our previous findings,30 this research effort revealed that freely
accessible thiol and disulfides play significant role in binding of proteins to AuNPs. Selective
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modification of proteins to increase the free thiols is, therefore, a viable way of increasing the
stability and robustness of the bioconjugates, and is the subject of Chapter 3.

2.4. Conclusions
Disulfides are often detected and quantified after reduction to their corresponding thiols
because they have no strong chemical signature. This research work confirms the strong affinity
of Au for sulfur in both freely accessible thiols and disulfides plays a significant role in
formation of a robust AuNP bioconjugates. Exploiting this unique interaction by modulating or
selectively modifying the amine residues of freely accessible lysine on proteins or antibodies for
specific orientation of antibodies to AuNP would eliminate common challenges often
encountered with direct immobilization techniques and advances a broader application of the
bioconjugates in drug delivery, diagnostic, nanomedicine and therapeutics. In this regard, we
further probe at the significance of chemically modifying proteins using Traut’s reagent to
increase the number of free thiols in order to the study the effect of increasing free thiols on
formation of robust bioconjugates. Gaining understanding into this, could be of great impact in
the development of strategies for systematic release of API (active pharmaceutical ingredients) in
drugs using bioconjugates as drug delivery vehicles.
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CHAPTER III: THE ROLE OF FREE THIOL ON PROTEIN ADSORPTION TO AuNPs

3.1. Introduction
Functionalized gold nanoparticles have been integrated into many novel biomedical
applications,1,84-86 including in vitro diagnostic testing,87 cellular imaging,88,89 photothermal
therapy,90 and drug delivery.91 Central to the success of these emerging AuNP-enable
technologies is well-controlled surface chemistry to facilitate targeted binding,92 cellular
uptake,93,94 low toxicity,95,96 and evasive properties97-100 as the downstream application demands.
Gold nanoparticles are commonly pre-functionalized with proteins to impart the desired
functionality prior to implementation in a biological application. Yet, despite efforts to control
the surface chemistry, it is well-established that, upon exposure to a biological fluid, a protein
corona forms around the bioconjugate that can alter the composition of the adsorbed protein
layer, and consequently, the intended function of the bioconjugate.101-106 Thus, it is imperative to
understand the fundamental mechanism by which proteins interact with the AuNP to mitigate
loss of function due to desorption of the pre-formed protein layer or to enable the controlled
release of the therapeutic proteins.107
Numerous early studies reported that the final composition of the protein corona is
thermodynamically determined.108,109 These studies were based on the introduction of an
unconjugated AuNP to a mixture of proteins in which most abundant protein adsorbs first, but
evolves such that the final composition of adsorbed protein correlates with binding affinity, e.g.,
Vrooman effect. The binding affinity is a combination of several forces, including electrostatic,
hydrophobic (entropically driven), and covalent Au-S chemisorption through cysteine residues.
Of these interfacial forces, the Au-S interaction is greatest;49,111 thus, one could conclude that the
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greater the number of thiols presented by a protein the greater the adsorption affinity and greater
representation on the AuNP surface. In several recent works using engineered proteins that vary
the number of free cysteine residues.Fitzkee and Zhang present compelling evidence that
cysteines are responsible for the affinity of protein to the AuNP surface and ultimately govern
the protein corona on the AuNP surface.47, 112-114
The presumed Vrooman effect is thermodynamically driven, which is predicated on
reversible protein-AuNP binding. However, published works demonstrate irreversible binding
for some protein systems,47, 30, 113, 115 which does not represent thermodynamic behavior and
precludes Langmuir-type predictive behavior of the protein corona in a multicomponent system.
These observations do not contradict the previously observed correlation between protein
thiolation and corona composition, but instead suggest that the order of protein adsorption may
play a more significant role than protein affinity, assuming the pre-adsorbed protein irreversibly
adsorbs to AuNP. To this point, Siriwardana et al., demonstrated that the composition of the final
protein adlayer on AuNP can vary for multi-protein systems with equivalent protein
concentrations when the sequence of protein addition is changed.112 It should be noted that these
studies did not remove excess pre-adsorbed protein from the as-formed conjugate prior to
subsequent exposure to a competing protein, and is appropriate for probing equilibrium behavior.
However, these experimental conditions are not representative of a nanobiotechnology
application in which the bioconjugate would be purified to remove excess free protein from the
suspension of the pre-functionalized conjugate prior to mixing with a biological medium.
Our lab has previously found that IgG antibody irreversibly adsorbs to AuNPs. Moreover,
the purified AuNP-antibody conjugate resists protein exchange when incubated with abundant
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plasma proteins or whole blood serum for a minimum of 24 hours.30 In that work, we postulated
that the antibody irreversibly chemisorbs to the AuNP through the formation of an Au-S bond
between cysteine and the AuNP. Moreover, we speculated that the IgG molecule presents a
greater number of free sulfhydryls than the other plasma proteins to resist protein exchange.
However, we did not consider protein adsorption order. It is possible that the antibody resisted
desorption because it was allowed to adsorb first, whereas pre-adsorption of a serum protein such
as human serum albumin (HSA) to form an HSA-AuNP conjugate could potentially resist
desorption by the antibody. Here we aim to systematically vary the number of free thiols on HSA
through chemical modification of lysine residues with 2-iminothiolane (Traut’s reagent) to
elucidate the role of free sulfhydryls on the synthesis of protein-AuNP conjugates. Additionally,
we investigate the potential effect of protein adsorption order on the composition of the final
protein layer.
3.2. Experimental
3.2.1. Reagents
Citrate-capped, spherical gold nanoparticles (AuNPs) with a nominal diameter of 60 nm
were purchased from Ted Pella Inc. (Redding, CA). Mouse anti-horseradish peroxidase
monoclonal antibody (anti-HRP; clone 2H11) was obtained from MyBioSource with a stock
concentration of 4.4 mg/mL. Human serum albumin (HSA) and ethylenediaminetetraacetic acid
(EDTA) were obtained from Sigma-Aldrich (St. Louis, MO). Horseradish peroxidase (HRP),
2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) (1-Step ABTS), potassium cyanide, 5,5'dithio-bis-(2-nitrobenzoic acid) (DTNB; Ellman’s reagent), 2-iminothiolane (Traut’s reagent),
and tris-(2-carboxyethyl) phosphine hydrochloride (TCEP) immobilized onto 4% crosslinked
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beaded agarose were purchased from Thermo Scientific (Rockford, IL). Potassium phosphate
monohydrate was acquired from Fisher Scientific (Fair Lawn, NJ) and anhydrous potassium
phosphate dibasic was purchased from Mallinckrodt Chemicals, Inc. (Paris, KY). All buffers and
aqueous solutions were prepared with deionized water (18 MΩ) from a Barnstead water
purification system (Thermo Scientific, Rockford, IL).
3.2.2. Chemical Modification of HSA
Twenty-fold and thirty-fold molar excess of Traut’s reagent was added to HSA and
allowed to react for 60 minutes at room temperature. Traut’s reagent reacts with the primary
amine of the lysine residue to introduce a free thiol group. The chemically modified HSA was
purified by removing excess, unreacted Traut’s reagent using a Zeba spin desalting column
(Thermo Scientific), following the manufacturer’s protocol. Throughout this work we refer to
these chemically modified HSA proteins collectively as T-HSA, and specifically as 20T-HSA
and 30T-HSA for preparation with 20-fold, and 30-fold molar excess of Traut’s reagent,
respectively. The concentration of recovered protein was determined using a Nanodrop 2000
(Thermo Scientific), and the extent of chemical modification, i.e., quantity of free thiols, was
determined using Ellman’s reagent.
3.2.3. Quantitation of Free Thiol
Ellman’s reagent was used to quantify the free thiol groups present in IgG, HSA and
Traut’s reagent modified HSA (T-HSA). Each protein was dissolved in 2 mM phosphate buffer
(pH 7.4) and the protein concentration was determined using a Nanodrop 2000. Cysteine
standards ranging from 50-800 mM were prepared in 2 mM phosphate buffer (pH 7.4). Ellman’s
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reagent was prepared at 4 mg/mL in 0.1 M phosphate buffer (pH 8.0) and 150 mL were added to
each reaction well of a 96-well plate. Protein sample (10 ml) or cysteine standard (10 ml) was
added to the reaction well and allowed to react with Ellman’s reagent for 30 min at room
temperature. After incubation, the absorbance was recorded at 415 nm with a BioRad iMark
Microplate reader. The concentration of free thiol in the protein samples was determined from
the calibration curve generated from the cysteine standard solutions, and the ratio of free thiol
concentration to protein concentration was calculated to quantify the absolute number of free
thiols per protein. Measure-IT Thiol Assay Kit (Thermo Scientific), a fluorescence-based kit,
was also used to quantify the number of free thiols per protein and confirm the result of the
Ellman’s reagent assay.
3.2.4. Reduction of Solvent Accessible Disulfide on Proteins
A reducing gel slurry (40 mL) consisting of TCEP immobilized onto 4% crosslinked
beaded agarose was centrifuged at 1000g for 1 min, the supernatant was discarded, and the resin
was resuspended in 2 mM phosphate buffer containing 2 mM EDTA. The resin was centrifuged
and washed with buffer two additional times. After the third centrifugation the supernatant was
discarded and 20 mL of protein was added directly to the pelleted resin. The protein/resin slurry
was vortexed and incubated 15 min at room temperature to reduce surface accessible disulfide
bonds in the protein. Following the reduction step, the suspension was centrifuged at 1000g for 1
min and the supernatant containing the reduced protein was collected. The concentration of
recovered, reduced protein was measured using a Nanodrop 2000 and the quantity of free thiols
was determined using Ellman’s reagent.
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3.2.5. Synthesis of Protein-AuNP Conjugates
The protein-AuNP bioconjugates were prepared by loading 100 μL of 60 nm AuNPs in a
low binding microcentrifuge tube followed by centrifugation at 5000g for 5 min. The supernatant
was discarded, and the pelleted AuNPs resuspended in 2 mM phosphate buffer at pH 7.4. Excess
protein to ensure monolayer coverage (200 nM antibody, 60 µM HSA, or 60 µM T-HSA) was
then added to the AuNP suspension, thoroughly mixed, and incubated for 60 min at room
temperature with gentle agitation.30 After allowing for the protein to adsorb onto the AuNP
surface, the suspension was centrifuged at 5000 g for 5 min to remove excess protein. The
protein-AuNP conjugate was resuspended in 2 mM phosphate buffer (pH 7.4), and the
centrifugation/resuspension cycle was repeated three additional times to thoroughly remove
excess protein.
3.2.6. Probing Protein Exchange on the Protein-AuNP Bioconjugate
Displacement of pre-adsorbed protein from the AuNP surface by the introduction of
competing proteins to the protein-AuNP bioconjugate was quantified using a previously reported
procedure.45,46 Briefly, 60 µM HSA, or 60 µM T-HSA was added to the suspension of purified
anti-HRP-AuNP bioconjugate, vortexed, and incubated for 3 or 24 h to allow for protein
exchange on the AuNP surface. Similarly, 200 nM anti-HRP antibody was added to the
suspension of prepared HSA-AuNP and T-HSA-AuNP bioconjugates, thoroughly mixed, and
incubated for 3 or 24 h. After allowing for potential protein exchange on the AuNP surface, the
bioconjugates were centrifuged at 5000g for 5 min and the supernatant was discarded to remove
any unbound or displaced proteins. The bioconjugates were resuspended in 2 mM phosphate
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buffer (pH 7.4) and three additional centrifugation/resuspension cycle were performed to
thoroughly remove any excess protein from the bioconjugates.
The extent of protein displacement was quantified following an enzymatic assay to
determine anti-HRP antibody loading on the conjugates.30, 49, 116 The purified bioconjugate
suspensions were incubated with excess HRP (3 µL, 1 mg/mL) for 1 h to saturate all antigen
binding sites presented by anti-HRP antibody on the AuNP bioconjugate. Next, excess HRP was
removed from the conjugates via four centrifugation/resuspension cycles. Using a 96-well plate,
10 µL of the conjugate was mixed with 150 µL of 1-Step ABTS solution. The HRP-catalyzed
reaction rate for the oxidation of ABTS was monitored by the absorption of the product at 415
nm for 20 min at 10 s intervals. The reaction rate was normalized to the concentration of
bioconjugates, measured with ICP-OES. A linear correlation was found between the reaction rate
and HRP concentration, thereby providing an indirect measure of antibodies adsorbed onto the
AuNP surface.
3.2.7. Protein and Bioconjugate Characterization
(i) Bioconjugate Quantitation with ICP-OES. Bioconjugate concentration was determined by
ICP-OES. To achieve this, 50 µL of the bioconjugate was loaded into a low binding tube and 5
µl of 100 mM potassium cyanide was added to dissolve the AuNPs and thus desorb the proteins
for direct quantitation of total Au. After dissolution, the clear solution was diluted to a final
volume of 5.00 mL with 2% nitric acid. Calibration standards were prepared in 2% nitric acid
with Au concentrations ranging from 0.1 ppm to 10 ppm. The prepared samples and Au
calibration standards were analyzed via ICP-OES. The samples were introduced at 1 mL/min
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into the plasma operating at 1500 W, and the emission intensity at 242.795 nm was integrated for
15 s.
(ii) Dynamic Light Scattering (DLS) and Zeta Potential. A Malvern Zetasizer Nano ZSP was
used to analyze the mean hydrodynamic diameter and zeta potential of HSA, T-HSA, anti-HRP
antibody, and protein-AuNP bioconjugates. All protein samples were prepared with pre-filtered
buffer (0.020 µm Anodisc filter) at ~1 mg/mL. A folded capillary cell was filled with buffer and
a 20 µL aliquot of sample was carefully added to the bottom of the folded capillary cell which is
interrogated by the laser (diffusion barrier technique). DLS was performed first to determine the
hydrodynamic diameter of the proteins and bioconjugates. Subsequently, the zeta potential was
measured, followed by an additional DLS measurement to confirm that the proteins did not
aggregate in the applied electric field during the zeta potential measurement.
3.3. Results and Discussion
3.3.1. Chemical Modification and Characterization of HSA
Our group recently established antibody exhibits a greater adsorption affinity to AuNPs
than HSA to form a robust conjugate. We hypothesize that free thiols on the protein are
responsible for the protein-AuNP affinity, thus, we postulate that adsorption affinity can be
controlled through chemical modification of proteins to increase the number of free thiol
functional groups. To test our hypothesis, we first quantified the number of free thiols on native
HSA and anti-HRP antibody using Ellman’s reagent (Figure 18, Table 3).79 Surprisingly, no free
thiols were detected on the antibody, while HSA presented 1.3 ± 0.6 free thiols per HSA
molecule (Table 3).
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Figure 18. Quantification of free thiols in proteins using DTNB (Ellman’s reagent). (A)
Chemical reaction between DTNB and free thiols presented by cysteine residues. (B) Calibration
curve and linear best fit for calibration standards of cysteine.
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Table 3. Quantity of free thiols per protein molecule determined by Ellman’s reagent.
Protein

Free Thiol per Protein

HSA

1.3 ± 0.6

20T-HSA

5.50 ± 0.01

30T-HSA

19.5 ± 2.8

HSA (reduced)

1.000 ± 0.003

Anti-HRP (reduced)

10.00 ± 0.06

These results were confirmed with a more sensitive fluorescence-based thiol quantitation
assay (Figure 19), which resulted in 0.9 ± 0.1 free thiols per HSA and no detectable thiols on the
antibody. Figure 20 A shows a molecular model of HSA (Protein Data Bank ID 1UOR117) and
reveals 34 of 35 cysteine residues are involved in disulfide bonding, and therefore not detectable
by Ellman’s reagent nor the thiol-reactive fluorescent dye.118 The anti-HRP antibody used in our
experimental studies is not sequenced; however, the structure is approximated by the molecular
simulation of a fully characterized mouse IgG protein (Protein Data Bank ID 1IGT).119
Figure 20 B shows that all cysteine residues in the IgG protein are involved in disulfide
bonding and not present as free thiols. The results of these protein structural models support the
experimentally measured free thiol functional groups on native HSA and anti-HRP antibody.
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Figure 19. Quantification of free thiols in proteins using the commercially available
fluorescence-based assay to quantify free thiols. Calibration curve and linear best fit for
calibration standards of cysteine.

Prior to molecular modeling, we had expected to measure a greater number of free thiols
on the antibody than the HSA molecule given the relative adsorption affinity of these two
proteins to AuNPs;30 however, it is important to note that the thiol quantitation assays are not
sensitive to disulfides.79 It is well-established that disulfide bonds cleave in the presence of a
gold surface to form a more stable S-Au bond.120 To more accurately measure the number of
thiol points of contact, including those present as disulfides in the native protein, the proteins
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were treated with TCEP to reduce disulfides and form thiols. In these experiments, TCEP was
immobilized on a resin rather than free in solution.

Figure 20. Illustration of protein exchange, where anti-HRP antibody is preadsorbed onto AuNP
and HSA is added to the purified AuNP-antibody conjugate to allow for potential protein
exchange (A). Normalized reaction rates for HRP captured by conjugates after allowing for
potential protein exchange (B).
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This immobilization of the reducing agent prevented penetration of TCEP into the protein
and only allowed reduction of surface accessible disulfides, simulating the effect of AuNP
contact. HSA and antibody were both treated with resin supported TCEP to reduce accessible
disulfides and Ellman’s reagent was used to quantify the free thiols of the TCEP-reduced
proteins. Table 3 shows that the TCEP-treated HSA did not increase the number of free thiols
(1.000 ± 0.003 thiol/HSA); however, TCEP-treated antibody produced 10.0 ± 0.06 free thiols per
antibody. This result suggests that the disulfide bridges are more surface accessible on the IgG
than the HSA molecules. To corroborate this experimental result, the solvent accessibility of
each amino acid in HSA and IgG was calculated and given a value ranging from 0 to 9 to semiquantitatively describe solvent accessibility for the native protein, where 0 indicates the amino
acid is completely inaccessible and 9 indicates the amino acid is fully exposed.121, 122 With this
model only three cysteine residues in HSA yielded a value of 3 or greater, indicating low to
moderate surface-accessible for interacting with AuNP, while all other cysteine residues were
buried within the folded HSA molecule and not accessible to bind to AuNP (surface accessibility
value < 3) (Figure 21 A). The IgG contains six cysteine residues with a value of 3 or greater,
suggesting that these amino acids may interact with the AuNP surface to trigger disulfide
reduction and formation of an Au-S bond, and potentially lead to structural changes that further
expose additional disulfides (Figure 21 B). These computational results are consistent with the
experimental observations regarding disulfide reduction of HSA and IgG to generate free
sulfhydryls. Collectively, these data suggest that native HSA binds to AuNP through a single
thiol moiety. Moreover, each antibody is immobilized to the AuNP through multiple S-Au
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interactions, although we note that it is not probable that all thiols are located in a position to
simultaneously interact with the AuNP.

A

B
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Figure 21. Molecular simulation to assess surface accessibility of each amino acid in HSA (A)
and IgG (B). The IgG sequence is presented as four chains. Each amino acid is assigned a score
between 0 and 9, where 0 represents the least solvent accessibility and 9 represents the greatest
solvent accessibility.
Next, we aimed to systematically vary the number of thiols through chemical
modification of HSA and identify any correlation between the number of thiols per protein and
protein-AuNP binding affinity. To this end, HSA was treated with Traut’s reagent, which reacts
with primary amines present on lysine residues to produce a terminal thiol (Figure 22). Traut’s
reagent was selected as a chemical modifier because this chemistry does not alter the protein
charge; the positive charge of the lysine is retained in the modified amino acid. This is an
important consideration given that previous reports have implicated protein charge in the
kinetics, orientation, and affinity of protein-AuNP binding.49, 113, 123
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Figure 22. Chemical modification of lysine residues in a protein with Traut’s reagent to increse
the number of free thiols.
HSA was first modified with 20-fold molar excess of Traut’s reagent to result in a total of
5.50 ± 0.01 thiols per HSA molecule (Table 3). To increase thiolation, HSA was also treated
with 30-fold molar excess of Traut’s reagent at pH 9.0, which has been reported to react with
phenols in addition to amines.124 Under these reaction conditions HSA was thiolated to introduce
a total of 19.5 ± 2.8 thiols groups per HSA molecule (Table 3). Generating this highly thiolated
HSA species was of particular interest because it contained more thiols than the antibody and
enabled us to further test the hypothesis that the number of thiols govern protein-AuNP
adsorption affinity.
After establishing that thiolation can be controlled through chemical modification, it was
necessary to confirm that the modification does not induce protein unfolding or aggregation. The
hydrodynamic diameters of HSA and T-HSA were analyzed by DLS and measure 8.1 ± 0.2 nm
and 7.6 ± 0.3 nm, respectively (Figure 24 A). These results are consistent with the known size of
HSA (8 nm x 3 nm)117 and the previously measured hydrodynamic diameter of HSA.123 The
similar sizes of HSA and T-HSA confirmed that chemical modification with Traut’s reagent did
not cause the protein to unfold or aggregate.
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Figure 23. Illustration of protein exchange, where variants of HSA are preadsorbed onto AuNP
and anti-HRP antibody is added to the purified AuNP-HSA conjugate to allow for potential
protein exchange (A). Normalized reaction rates for HRP captured by conjugates after allowing
for potential protein exchange (B).
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AuNP and anti-HRP antibody is added to the purified AuNP-HSA conjugate to allow for
potential Our results are consistent with previously reported chemical modification to succinylate
and aminate HSA which did not result in protein unfolding nor aggregation.123 While unfolding
of HSA and T-HSA is not paramount to elucidate the role of thiolation on adsorption affinity, it
is significant to demonstrate that thiolation is possible without protein denaturation. This
provides a potential pathway to enhance protein adsorption to AuNP while maintaining
biofunctionality of the bioconjugate for downstream applications.

Figure 24. Characterization of HSA and modified HSA. Histogram of hydrodynamic diameter
measured with DLS (A) and zeta potential (B) of unmodified and modified HSA.

The protein charge was also measured to evaluate the impact of chemical modification.
Previous works have established that protein charge significantly impacts adsorption affinity and
protein orientation,49, 123 and likely contributes to the adsorption kinetics for protein-AuNP
interactions.113 Guided by these previous findings, we aimed to maintain a constant protein
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charge among all HSA species to eliminate electrostatic interactions as a variable during protein
adsorption studies, and modification with Traut’s reagent was not expected to alter the protein
charge. Zeta potential was measured to assess any changes in the protein surface charge and
Figure 24 B shows a measured zeta potential of -4.6 ± 0.4 mV and -5.9 ± 0.5 mV for HSA and
T-HSA, respectively. The protein charge did not statistically differ after chemical modification
and this result alleviates any concern regarding charge-dependent adsorption effects.
3.3.2. Characterization of Protein-AuNP Conjugates
Native HSA, thiolated HSA, or antibody was mixed with AuNPs to allow spontaneous
adsorption of the protein onto the AuNP surface, thereby forming bioconjugates. The
bioconjugate was formed with a large excess of protein to ensure that the protein saturates the
AuNP at monolayer coverage.74,125-127 The hydrodynamic diameters of the HSA-AuNP and THSA-AuNP bioconjugates measured 68.5 ± 0.2 nm and 68.9 ± 0.2 nm, respectively (Figure 24
A). This is an increase of 6 nm in diameter relative to the unconjugated AuNP which measured
62.3 ± 0.2 nm and is representative of a fully formed monolayer of protein.

Figure 25. Characterization of protein-AuNP conjugates. (A) Histogram of hydrodynamic
diameter measured with DLS. (B) Zeta potential of unconjugated and conjugated AuNP. (C)
UV-visible extinction spectra of unconjugated and conjugated AuNP.
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These data also confirm that the HSA-AuNP and T-HSA-AuNP conjugates were stable
and the protein did not induce aggregation. Given the inherent sensitivity of DLS to aggregates,
the presence of only a few aggregates would lead to greater than expected measured value of the
population mean hydrodynamic diameter, e.g., ~68 nm.59 The antibody-AuNP conjugate was
stable and formed a bioconjugate with a mean hydrodynamic diameter of 87 nm, which reflects
the larger size of IgG compared to HSA.61
We measured the zeta potential of the unconjugated and protein-AuNP bioconjugates as
an orthogonal metric to confirm the formation of protein-AuNP conjugates. Unconjugated AuNP
exhibited a zeta potential of -43 ± 3 mV that results from the adsorbed citrate capping agent that
forms during synthesis (Figure 25 B). Adsorption of HSA, T-HSA, and antibody onto AuNPs
shifted the zeta potential to -27 ± 2 mV, -26 ± 2 mV, and -19 ± 2 mV, respectively (Figure 25 B).
These increases in zeta potential are consistent with other reported zeta potential values for
protein-AuNP conjugates,108, 128 and the similar values for HSA and T-HSA formed
bioconjugates suggest similar protein loading for both proteins given that each protein has a
similar charge.
The binding of HSA, T-HSA, and antibody to AuNP was also assessed by extinction
spectrophotometry. The unconjugated AuNP displayed an extinction maximum at 537 nm
(Figure 25 C). The formed HSA-AuNP and T-HSA-AuNP conjugates both resulted in a 2-nm
red shift relative to the unconjugated AuNP to exhibit extinction maxima at 539 nm (Figure 25
C). This shift in extinction is characteristic of a change in local refractive index at the AuNP
surface and is expected for the adsorption of a protein layer with a modest thickness such as
HSA.129, 130 Adsorption of a larger protein, such as an antibody, results in a thicker proteinaceous
layer to produce a greater red shift in the extinction, e.g., lmax = 542 nm (Figure 25 C).
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3.3.3. Protein Displacement
In our previous work we established that antibody irreversibly adsorbs to AuNP.30 Upon
removal of excess antibody to purify the antibody-AuNP conjugate and resuspension in buffer,
the antibody did not desorb over a period of seven days. Moreover, introduction of plasma
proteins into a suspension of the purified antibody-AuNP conjugate did not disrupt the antibodyAuNP interaction and no protein exchange was detected. In that work, we attributed the resilient
antibody-AuNP interaction to a greater number of cysteine residues on the antibody compared to
the other plasma proteins. However, we did not rule out the possibility that any pre-adsorbed
protein, bound to the AuNP through a thiol, could resist protein exchange, and that protein
displacement from the AuNP is independent of the number of thiols contained in the protein.
Here, a series of protein exchange studies were performed with antibody, native HSA, and
thiolated HSA proteins to elucidate the role of accessible free sulfhydryl and to identify the key
factors that lead to irreversible adsorption, e.g., order of protein adsorption.
Our lab recently developed an enzyme-mediated assay to quantify protein exchange on
the surface of AuNPs.30, 49 Using this previously developed method, we first investigated the
ability of HSA and T-HSA to displace antibody pre-adsorbed on the AuNP. To this end, AuNP
was fully saturated with an adlayer of anti-HRP antibody via spontaneous adsorption and excess
antibody was removed to purify the antibody-AuNP conjugate. HSA, 20T-HSA or 30T-HSA was
then added to the fully formed antibody-AuNP conjugate at a concentration of 60 µM and
incubated for 3 h or 24 h to allow for protein exchange on the AuNP surface (Figure 20 A). This
concentration of HSA, 20T-HSA, and 30T-HSA corresponds to the normal HSA concentration in
10% serum and is ~30-fold molar excess of the HSA concentration required to form a monolayer
on unconjugated citrate-capped AuNP. 30, 128 A large excess of antigen (HRP) was added to the
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suspension to saturate all antigen binding sites that were presented by the antibodies remaining
on the AuNP surface after allowing for protein exchange. The captured HRP was quantified by
the enzymatic oxidation rate of ABTS (Figure 26) and provided an indirect measure of
immobilized antibody on the AuNP.

AuNPs

Figure 26. Enzyme kinetic reaction to quantify antibody immobilized on the AuNP.
As a positive control, and to define the maximum amount of antigen captured by a
conjugate, i.e., maximum amount of adsorbed antibody, antibody-AuNP was incubated in buffer
without a competing protein. The enzymatic reaction rates for all conjugates involved in protein
exchange studies were normalized with respect to the rate measured for this fully coated
antibody-AuNP conjugate (Figure 20 B). As a negative control HSA-AuNP conjugates were
synthesized and incubated with HRP to allow for non-specific interactions. Minimal enzymatic
activity was detected by the HSA-coated AuNP and confirmed HRP was only captured by the
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AuNP conjugate through specific interactions with immobilized anti-HRP antibody (Figure 20
B). Thus, we can conclude any normalized rate of less than 1.0 indicates fewer captured HRP
molecules due to the displacement of antibody from the conjugate surface in exchange for HSA.
Figure 20 B shows that HSA did not displace antibody after allowing 3 h or 24 h for protein
exchange, and is in agreement with our previous work.30 Similar results were observed for the
20T-HSA, in which the antibody resisted displacement by this chemically modified HSA
containing ~6 thiols. However, 30T-HSA displaced ~85% of antibody from the antibody-AuNP
conjugate after allowing only 3 h for protein exchange. Increased incubation to allow 24 h of
protein exchange did not lead to further displacement of antibody. These data repudiate the
possibility that order of adsorption determines bioconjugate protein composition and establishes
that pre-adsorbed proteins are susceptible to protein exchange. These results suggest that the
final composition of the protein layer on the AuNP is primarily governed by the total number of
free thiols that are solvent accessible (Table 3).
We conclude that protein exchange proceeded through an associative exchange
mechanism, rather than a dissociative mechanism. We previously demonstrated that the antibody
does not spontaneously desorb from the AuNP surface;30 thus, a dissociative ligand exchange
pathway is ruled out. While the antibody is fully saturating the AuNP surface, the random
adsorption process does not result in a close-packed adlayer, and it was previously demonstrated
that as much as 70% of the AuNP surface is still available for adsorption of small molecules that
penetrate the protein layer of a fully formed bovine serum albumin-AuNP conjugate.114 HSA is
smaller than IgG, and therefore, HSA can penetrate between the adsorbed antibody to interact
with the AuNP surface. However, displacement of the initially adsorbed antibody is only
possible by the 30T-HSA which exhibits a greater binding affinity than the IgG molecule. Here
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we observe ~85% protein exchange efficiency for the 30T-HSA, which is like ligand exchange
efficiencies of 75-90% measured for small thiol ligands on AuNP.130
To further test our suppositions proposed above, HSA or T-HSA was first pre-adsorbed
onto AuNP to form bioconjugates, followed by the addition of anti-HRP antibody to allow for
protein exchange (Figure 23 A). Antibody readily displaced the pre-adsorbed HSA from the
AuNP surface within 3 h to gain full antigen binding capacity equivalent to the positive control
anti-HRP-AuNP conjugate (Figure 23 B). Interestingly, the 20T-HSA displayed greater
resistance to displacement by the antibody than the native HSA. After 3 h of incubation, the 20THSA was partially displaced by antibody such that the conjugate recovered 31% of its antigen
binding capacity compared to the anti-HRP-AuNP conjugate. However, after 24 h of incubation,
antibody displaced 20T-HSA from the AuNP surface to fully recover antigen binding capacity
equivalent to the anti-HRP positive control conjugate. In contrast to HSA and 20T-HSA, Figure
23 B shows that the 30T-HSA-AuNP conjugate benefited from a more robust adsorptive
interaction, and this conjugate yielded 20-25% of the antigen binding activity of the fully formed
antibody-AuNP conjugate after allowing for protein exchange. Clearly, the data show that 30THSA resisted displacement by the antibody; however, minimal, yet significantly, antigen binding
activity was observed for this conjugate. The time-dependent results suggest that 30T-HSA and
antibody composition of the AuNP protein corona reached a steady-state after 3 h of incubation
since the antigen-binding activity did not increase with antibody exchange time. It is possible,
that this recovered antigen-binding capacity is due to the displacement of a few weakly adsorbed
30T-HSA molecules that were oriented such that only a few thiols interacted with the AuNP
surface.
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Figure 27. Model of HSA (PDB ID 1UOR) (A) and IgG (PDB ID 1IGT) (B). Cysteine
residues are highlighted in yellow and yellow lines connect cysteine residues that form disulfide
bridges.
Alternatively, the antibody may backfill any available space on the AuNP surface, given
that the HSA adlayer is disordered and only passivates ~70% of the Au surface to result in a
mixed protein layer with minimal antigen-binding activity. However, the antibody, with 10
available thiols, does not displace the adsorbed 30T-HSA, which contains 20 free thiols. In
contrast, the antibody backfills “pinholes” in the HSA and 20T-HSA conjugates, and then
displaces these weaker bound HSA variants that display fewer free thiols than the antibody.
Notably, these results demonstrate that as the number of thiols on the modified HSA exceed the
number of thiols on antibody, the HSA protein can resist displacement by antibody. Moreover,
these protein exchange studies with pre-adsorbed HSA and chemically modified HSA provide
further evidence that protein adsorption onto AuNP is governed by the number of free and
accessible thiols. Most significantly, this model protein system provides evidence for controlled
release of immobilized proteins through thiolation, as specifically demonstrated by the 20THSA-AuNP conjugate.
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3.4. Conclusion
Here, we performed ligand exchange studies to probe the role of free sulfhdryls on protein
adsorption and the impact of protein adsorption sequence using an IgG monoclonal antibody and
chemically modified variants of HSA using Traut’s reagent. A key finding is that thiols can be
added to proteins to control the total number of free sulfhydryls on each protein molecule, and
the chemically modified protein remains stable, e.g., folded and non-aggregated. This chemical
modification protocol allows for controlling adsorption affinity through facile chemical treatment
of protein, which is much more time- and cost-effective than protein engineering strategies to
synthesize mutant proteins with a defined number of cysteine residues.113
Ligand exchange studies using the chemically modified HSA led to four key outcomes.
First, pre-adsorbed protein is only displaced from the AuNP surface by proteins in solution that
contain more thiols. This finding is consistent with those reported for the relative stability of
engineered GB3(0-2) proteins adsorbed onto AuNPs. Second, the composition of the final protein
corona on the AuNP surface is independent of the order in which the proteins are added to the
AuNP. Third, we observe that small proteins with many thiols outcompete larger proteins that
have more overall interactions, e.g., electrostatic, hydrophobic, etc., yet have fewer thiol
moieties. Previous research has reported that protein binding affinity correlates with protein
molecular weight; however, that is likely due to larger proteins having a greater probability of
containing more cysteine residues, unless smaller proteins are engineered or chemically modified
to increase the number of fee thiols, as was done in this work. Last, we observe that the protein
exchange rate is dependent on the difference between the number of thiols on the pre-adsorbed
protein and the competing protein, with slower exchange rates for similar number of thiols.
Collectively, we conclude from our data that the number of Au-S bonds is the dominant
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attractive force between proteins and AuNP and are ultimately responsible for the final protein
corona. These findings present an exciting opportunity to carefully control protein adsorption
affinity through chemical modification to protect against desorption of pre-adsorbed protein and
loss of function or enable time-controlled release for therapeutic applications.
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CHAPTER IV: CONCLUSION

4.1. Research Summary
Developing a robust and highly sensitive AuNP-antibody based assay for early detection
of infectious diseases such as influenza and coronavirus is a novel research area. Urgent
actualization of this goal was mandated by the challenges facing infectious disease diagnosis.
Central to these challenges, is the use of sophisticated and expensive diagnostic instruments (e.g.
reverse transcriptase polymerase chain reaction for diagnosis of coronavirus) together with long
procedures that leads to eventual long period of time for the diagnosis results.18 In this work, we
are tailoring the research efforts towards development of a model, that would make diagnostic
tools for early detection of infectious diseases and any other emerging diseases readily available
and accessible to all. Immunoassays such as this, should be readily synthesized and be able to
perform to the optimum within a short period of time.
Our effort so far has been centered on understanding the mechanisms of interaction of
proteins, especially antibodies, with AuNPs, and how this interaction can be explored towards the
formation of a robust and highly oriented bioconjugate to favor early detection of diseases.
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4.2. Quantitation of Free Sulfhydryl in Blood Proteins
Formation of a robust and sensitive assay is a relative term, which depends largely on the
complex nature of the matrix the assay passing through in the path to hit its target. Therefore, we
sought to test the resistivity of our synthesized AuNP-antibody bioconjugate to
displacement/replacement by the most prominent blood proteins. These blood proteins are the
main component of the blood, the main medium for diagnosis of diseases as well as therapeutic
treatments and vaccination. In these studies, we were able to ascertain that our synthesized
AuNP-antibody bioconjugates are robust enough to resist displacement by blood proteins.
Subsequently, we sought to understand the unique property of antibody that other blood proteins
lack. Our studies revealed the significant role thiols played in the formation of such a robust
conjugate, as antibody possesses more accessible thiols than all blood proteins used in this
research work.
In order to further substantiate this finding, we chemically modified the most abundant
blood protein, HSA with equal molar of DSP and Traut’s reagent with each reacting with lysine
residues to produce two and one thiols respectively. Displacement studies of these chemically
modified proteins revealed and confirmed that thiols play significant role in adsorption of
proteins to AuNPs as the DSP-modified HSA resisted being displaced by antibody much more
(~4x) than Traut’s reagent modified HSA.
4.3. The Role of Free Thiol on Protein Adsorption to Gold Nanoparticles
Accessible disulfides and thiols in proteins are very important in adsorption of proteins to
AuNPs. To further evaluate the significance of this finding, we set to quantify the number of free
thiols present in HSA and chemically modulate the number of free thiols in the protein through
varying molar excess of Traut’s reagent. The outcome of this research effort revealed that
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proteins adsorption to AuNP can be enhanced by chemically increasing the number of free thiols
accessible for binding to AuNPs.
We can therefore conclude from this research efforts that formation of a robust and stable
AuNP-antibody conjugates that withstands deactivation/inactivity by encountering complex
matrixes can be achieved. Understanding the nature of interaction between proteins and AuNP,
as due to formation of Au-S bonds, we can explore this mechanism to build a model for
diagnostic assay in early detection of infectious diseases.

4.4. Outlook
The long-term goal of this research group is to develop nanoparticle-based platforms for
early detection and treatment of diseases. We can further this research to meet the challenges
facing humanity today by employing these studies to advance development in
nanomedicine.Systematical chemical modification of fragment crystallizable region of antibodies
using Traut’s reagent would lead to a directional adsorption of antibodies to AuNPs. This
selective modification would not only enhance the formation of a robust conjugate but also
favors a well oriented assay for a fast and early detection of diseases and pharmaceutical delivery
vehicles. Development of a novel model for synthesizing bioconjugates for diagnosis of diseases
and other biomedical applications can be achieved by integrating this new research work and the
findings in this work.
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